Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Get Free Report) EVP Eliyahu Sharon Kalif sold 106,563 shares of the stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $34.10, for a total transaction of $3,633,798.30. Following the transaction, the executive vice president directly owned 65,621 shares in the company, valued at $2,237,676.10. The trade was a 61.89% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Eliyahu Sharon Kalif also recently made the following trade(s):
- On Thursday, May 14th, Eliyahu Sharon Kalif sold 153,251 shares of Teva Pharmaceutical Industries stock. The stock was sold at an average price of $35.61, for a total value of $5,457,268.11.
Teva Pharmaceutical Industries Stock Down 3.3%
Shares of Teva Pharmaceutical Industries stock opened at $31.50 on Friday. The business has a 50-day moving average price of $33.50 and a 200 day moving average price of $32.20. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $14.99 and a fifty-two week high of $37.35. The firm has a market cap of $36.22 billion, a P/E ratio of 23.68, a P/E/G ratio of 3.32 and a beta of 0.84. The company has a quick ratio of 0.78, a current ratio of 1.01 and a debt-to-equity ratio of 1.70.
Analyst Ratings Changes
A number of equities analysts have commented on the stock. Barclays lifted their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Bank of America increased their target price on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, April 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Monday, April 20th. JPMorgan Chase & Co. boosted their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Finally, Truist Financial increased their price objective on shares of Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $41.78.
Get Our Latest Stock Report on Teva Pharmaceutical Industries
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the stock. Norges Bank acquired a new position in shares of Teva Pharmaceutical Industries during the fourth quarter valued at $1,098,060,000. WCM Investment Management LLC increased its holdings in shares of Teva Pharmaceutical Industries by 191.4% in the 1st quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock worth $1,157,264,000 after acquiring an additional 26,813,522 shares during the period. Harel Insurance Investments & Financial Services Ltd. increased its holdings in shares of Teva Pharmaceutical Industries by 19.2% in the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company’s stock worth $1,402,945,000 after acquiring an additional 7,255,083 shares during the period. Wellington Management Group LLP lifted its position in Teva Pharmaceutical Industries by 39,228.4% in the 3rd quarter. Wellington Management Group LLP now owns 6,895,838 shares of the company’s stock valued at $139,296,000 after purchasing an additional 6,878,304 shares during the last quarter. Finally, Clal Insurance Enterprises Holdings Ltd lifted its position in Teva Pharmaceutical Industries by 18.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 37,404,106 shares of the company’s stock valued at $1,171,378,000 after purchasing an additional 5,917,423 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.
More Teva Pharmaceutical Industries News
Here are the key news stories impacting Teva Pharmaceutical Industries this week:
- Positive Sentiment: Teva submitted an NDA for ecopipam, backed by positive Phase 3 data published in JAMA Neurology, raising the possibility of the first FDA-approved pediatric Tourette treatment in more than a decade. Article Title
- Positive Sentiment: Ecopipam has already received FDA Orphan Drug and Fast Track designations, which can support development and review for a niche area with clear unmet medical need.
- Neutral Sentiment: Teva also announced it will host its second-quarter 2026 earnings call on July 29 and released an investor aide memo, which are routine updates and unlikely to move the stock on their own. Article Title
- Neutral Sentiment: The FDA’s broader request for updated labeling on testosterone therapies does not appear to directly target Teva, so its impact on TEVA is likely limited unless future details connect the company more directly. Article Title
- Negative Sentiment: Recent insider activity has been a headwind, with an executive vice president selling shares, adding to a pattern of insider selling that can weigh on sentiment. Article Title
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.
Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.
See Also
- Five stocks we like better than Teva Pharmaceutical Industries
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.
